Home Alzheimer’s Disease Parameswaran Hari, MD, MRCP, Discusses Lenalidomide Maintenance Outcomes in Multiple Myeloma

Parameswaran Hari, MD, MRCP, Discusses Lenalidomide Maintenance Outcomes in Multiple Myeloma

Parameswaran Hari, MD, MRCP, discussed the progression-free survival of patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program.

Transcription:

To our surprise, we found that the progression-free survival going forward was better if you stayed on (lenalidomide) maintenance. So, at 6 years, 79.5 maybe 80% of patients who were on (lenalidomide) continued to remain progression-free and alive. On the other arm, the people who stopped (lenalidomide), only 61%, so there’s a pretty dramatic drop off in the number of patients who progressed when they stopped (lenalidomide). This actually leads us to the conclusion that we have not been able to identify a point at which it is completely safe to stop (lenalidomide) maintenance even if you are progression-free at 3 years.

I…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments